Trial reportBritish journal of cancer2013
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
Trial report in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- The effect of BMI on survival outcome of breast cancer patients: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta-analysis.International journal of cancer · 2023Pooled it
- Associations of adiposity and weight change with recurrence and survival in breast cancer patients: a systematic review and meta-analysis.Breast cancer (Tokyo, Japan) · 2022Pooled it
- Impact of obesity on clinical outcomes in hormone receptor-positive breast cancer: a systematic review.Breast cancer (Tokyo, Japan) · 2021Pooled it
- The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.JNCI cancer spectrum · 2023Trial
- Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.International journal of cancer · 2019Trial
- Metabolic Endotoxemia Amplifies Estrogen Signaling Through Stromal Crosstalk in Obesity-Associated Breast Cancer.International journal of molecular sciences · 2026Article
- Alternate actions of CDK4/6 inhibitors beyond cell cycle blockade: unexplored roles in therapy resistance.Cancer metastasis reviews · 2025Review
- Complex Interplay Between Obesity and BRCA1/2-Associated Breast Cancer: An Overview.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation.NPJ breast cancer · 2024Article
- Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients.Scientific reports · 2023Article
- Obesity and Breast Cancer: Interaction or Interference with the Response to Therapy?Current oncology (Toronto, Ont.) · 2023Article
- Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer.Breast cancer research and treatment · 2023Article
- Breast cancer microenvironment and obesity: challenges for therapy.Cancer metastasis reviews · 2022Review
- The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer.NPJ breast cancer · 2022Article
- Hormonal Crosstalk Between Thyroid and Breast Cancer.Endocrinology · 2022Review
- Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer.Breast cancer research and treatment · 2022Article
- Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2022Review
- Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice.Frontiers in oncology · 2022Article
- Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer.NPJ breast cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe investigated whether body mass index (BMI) can be used as a predictive parameter indicating patients who benefit from extended aromatase inhibitor (AI) treatment.
methodsThe ABCSG-6a trial re-randomised event-free postmenopausal hormone receptor-positive patients from the ABCSG-6 trial to receive either 3 additional years of endocrine therapy using anastrozole vs nil. In this retrospective analysis, we investigated the prognostic and predictive impact of BMI on disease outcome and safety.
resultsIn all, 634 patients (177 normal weight, 307 overweight, and 150 obese) patients were included in this analysis. Normal weight patients with additional 3 years of anastrozole halved their risk of disease recurrence (disease-free survival (DFS) HR 0.48; P=0.02) and death (HR 0.45; P=0.06) and had only a fifth of the risk of distant metastases (HR 0.22; P=0.05) compared with normal weight patients without any further treatment. In contrast, overweight+obese patients derived no benefit from additional 3 years of anastrozole (DFS HR 0.93; P=0.68; distant recurrence-free survival HR 0.91; P=0.78; and OS HR 0.9; P=0.68). The possible predictive impact of BMI on extended endocrine treatment could be strengthened by a Cox regression interaction model between BMI and treatment (P=0.07).
conclusionBody mass index may be used to predict outcome benefit of extended AI treatment in patients with receptor-positive breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.